regranex
janssen-cilag international nv - becaplermin - wound healing; skin ulcer - preparations for treatment of wounds and ulcers - regranex is indicated, in association with other good wound care measures, to promote granulation and thereby the healing of full-thickness, neuropathic, chronic, diabetic ulcers less than or equal to 5 cm2.
trevicta (previously paliperidone janssen)
janssen-cilag international nv - paliperidone palmitate - schizophrenia - psycholeptics - trevicta, a 3 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly paliperidone palmitate injectable product.
janssen covid-19 vaccine- ad26.cov2.s injection, suspension
janssen products, lp - ad26.cov2.s (unii: jt2ns6183b) (ad26.cov2.s - unii:jt2ns6183b) - janssen covid-19 vaccine is authorized for use under an emergency use authorization (eua) for active immunization to prevent coronavirus disease 2019 (covid-19) caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in individuals 18 years of age and older for whom other fda-authorized or approved covid-19 vaccines are not accessible or clinically appropriate, and in individuals 18 years of age and older who elect to receive the janssen covid-19 vaccine because they would otherwise not receive a covid-19 vaccine. do not administer the janssen covid-19 vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the janssen covid-19 vaccine [see description (13)] . do not administer the janssen covid-19 vaccine to individuals with a history of thrombosis with thrombocytopenia following the janssen covid-19 vaccine or any other adenovirus-vectored covid-19 vaccine (e.g., astrazeneca's covid-19 vac
reminyl
janssen-cilag (new zealand) ltd - galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base; galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base - modified release capsule - 16 mg - active: galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base excipient: diethyl phthalate ethylcellulose gelatin hypromellose iron oxide red opacode black s-1-27794 opadry clear oy-7240 sugar spheres titanium dioxide active: galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-277002 opadry clear oy-7240 sugar spheres - reminyl is indicated for the treatment of mild to moderately severe dementia of the alzheimer type.
reminyl
janssen-cilag (new zealand) ltd - galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg; galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg - modified release capsule - 24 mg - active: galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose iron oxide red iron oxide yellow opacode black s-1-277002 opadry clear oy-7240 sugar spheres titanium dioxide active: galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-277002 opadry clear oy-7240 sugar spheres - reminyl is indicated for the treatment of mild to moderately severe dementia of the alzheimer type.
reminyl
janssen-cilag (new zealand) ltd - galantamine hydrobromide 10.25mg equivalent to galantamine base 8 mg; galantamine hydrobromide 10.25mg equivalent to galantamine base 8 mg - modified release capsule - 8 mg - active: galantamine hydrobromide 10.25mg equivalent to galantamine base 8 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-27794 opadry clear oy-7240 sugar spheres titanium dioxide active: galantamine hydrobromide 10.25mg equivalent to galantamine base 8 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-277002 opadry clear oy-7240 sugar spheres - reminyl is indicated for the treatment of mild to moderately severe dementia of the alzheimer type.
risperdal 4 mg film-coated tablets
janssen-cilag ltd - risperidone - tablets - 4 mg - other antipsychotic - it is indicated for the treatment of schizophrenia; for the treatment of moderate to severe manic episodes associated with bipolar disorders; in patients with moderate to severe alzheimer's dementia; forf persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation
risperdal 3 mg film-coated tablets
janssen-cilag ltd - risperidone - tablets - 3 mg - other antipsychotic - it al is used to treat the following: schizophrenia, mania, aggression in people with alzheimer’s dementia, aggression in intellectually disabled children (at least 5 years of age) and adolescents with conduct disorder.
janssen daratumumab daratumumab 400 mg/20 ml concentrated solution for infusion vial
janssen-cilag pty ltd - daratumumab -
janssen daratumumab daratumumab 100 mg/5 ml concentrated solution for infusion vial
janssen-cilag pty ltd - daratumumab -